The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Vaccines for the 21st century
Open accessAbstract
In the last century, vaccination has been the most effective medical intervention to reduce death and morbidity caused by infectious diseases. It is believed that vaccines save at least 2–3 million lives per year worldwide. Smallpox has been eradicated and polio has almost disappeared worldwide through global vaccine campaigns. Most of the viral and bacterial infections that traditionally affected children have been drastically reduced thanks to national immunization programs in developed countries. However, many diseases are not yet preventable by vaccination, and vaccines have not been fully exploited for target populations such as elderly and pregnant women. This review focuses on the state of the art of recent clinical trials of vaccines for major unmet medical needs such as HIV , malaria, TB , and cancer. In addition, we describe the innovative technologies currently used in vaccine research and development including adjuvants, vectors, nucleic acid vaccines, and structure‐based antigen design. The hope is that thanks to these technologies, more diseases will be addressed in the 21st century by novel preventative and therapeutic vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,808
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Pathogenesis of dengue: challenges to molecular biology
Halstead, S. (1988) · Science · doi:10.1126/science.239.4839.476 · Cited by 1,614
Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing
Pizza, M., Scarlato, V., Masignani, V., Giuliani, M. M., Aricò, B., Comanducci, M., Jennings, G. T., Baldi, L., Bartolini, E., Capecchi, B., et al. (2000) · Science · doi:10.1126/science.287.5459.1816 · Cited by 1,399
Self-citationEffectiveness of maternal influenza immunization in mothers and infants
Zaman, K., Roy, E., Arifeen, S. E., Rahman, M., Raqib, R., Wilson, E., Omer, S. B., Shahid, N. S., Breiman, R. F., & Steinhoff, M. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708630 · Cited by 1,227
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans
Querec, T. D., Akondy, R. S., Lee, E. K., Cao, W., Nakaya, H. I., Teuwen, D., Pirani, A., Gernert, K., Deng, J., Marzolf, B., et al. (2009) · Nature Immunology · doi:10.1038/ni.1688 · Cited by 1,121
Tameris, M. D., Hatherill, M., Landry, B. S., Scriba, T. J., Snowden, M. A., Lockhart, S., Shea, J. E., McClain, J. B., Hussey, G. D., Hanekom, W. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60177-4 · Cited by 1,049
The rgp120 HIV Vaccine Study Group (2005) · The Journal of Infectious Diseases · doi:10.1086/428404 · Cited by 952
The interface between innate and adaptive immunity
Hoebe, K., Janssen, E., & Beutler, B. (2004) · Nature Immunology · doi:10.1038/ni1004-971 · Cited by 916
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J. W., Choopanya, K., & Bangkok Vaccine Evaluation Group (2006) · The Journal of Infectious Diseases · doi:10.1086/508748 · Cited by 847
Sabchareon, A., Wallace, D., Sirivichayakul, C., Limkittikul, K., Chanthavanich, P., Suvannadabba, S., Jiwariyavej, V., Dulyachai, W., Pengsaa, K., Wartel, T. A., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61428-7 · Cited by 818
Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer
Julien, J.-P., Cupo, A., Sok, D., Stanfield, R. L., Lyumkis, D., Deller, M. C., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., et al. (2013) · Science · doi:10.1126/science.1245625 · Cited by 797
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al. (2013) · Science · doi:10.1126/science.1234150 · Cited by 770
Inflammatory Exposure and Historical Changes in Human Life-Spans
Finch, C. E., & Crimmins, E. M. (2004) · Science · doi:10.1126/science.1092556 · Cited by 754
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 741 · cited 1×
“RNA vaccines can also be engineered RNA replicons derived from certain RNA viruses lacking viral structural proteins which are capable of self-replication on delivery to the cytoplasm (Geall et al , 2012, 2013).”
Self-citationA universal vaccine for serogroup B meningococcus
Giuliani, M. M., Adu-Bobie, J., Comanducci, M., Aricò, B., Savino, S., Santini, L., Brunelli, B., Bambini, S., Biolchi, A., Capecchi, B., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603940103 · Cited by 727
Self-citationHIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
McElrath, M. J., De Rosa, S. C., Moodie, Z., Dubey, S., Kierstead, L., Janes, H., Defawe, O. D., Carter, D. K., Hural, J., Akondy, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61592-5 · Cited by 713
Rappuoli, R. (2000) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(00)00119-3 · Cited by 704
Self-citation(1992) · International Journal of Biochemistry · doi:10.1016/0020-711x(92)90281-5 · Cited by 671
Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer
Lyumkis, D., Julien, J.-P., de Val, N., Cupo, A., Potter, C. S., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., Carragher, B., et al. (2013) · Science · doi:10.1126/science.1245627 · Cited by 669
Schneider, J., Gilbert, S. C., Blanchard, T. J., Hanke, T., Robson, K. J., Hannan, C. M., Becker, M., Sinden, R., Smith, G. L., & Hill, A. V. S. (1998) · Nature Medicine · doi:10.1038/nm0498-397 · Cited by 644
Barouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses
Gaucher, D., Therrien, R., Kettaf, N., Angermann, B. R., Boucher, G., Filali-Mouhim, A., Moser, J. M., Mehta, R. S., Drake, D. R., Castro, E., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20082292 · Cited by 594
GIANNINI, S., HANON, E., MORIS, P., VANMECHELEN, M., MOREL, S., DESSY, F., FOURNEAU, M., COLAU, B., SUZICH, J., & LOSONKSY, G. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.005 · Cited by 496
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Use of a Staphylococcus aureus Conjugate Vaccine in Patients Receiving Hemodialysis
Shinefield, H., Black, S., Fattom, A., Horwith, G., Rasgon, S., Ordonez, J., Yeoh, H., Law, D., Robbins, J. B., Schneerson, R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011297 · Cited by 474
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O. K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M., Lifson, J. D., et al. (2013) · Nature · doi:10.1038/nature12746 · Cited by 455
Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
Ottenhoff, T. H. M., & Kaufmann, S. H. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002607 · Cited by 455
Davis, B. S., Chang, G.-J. J., Cropp, B., Roehrig, J. T., Martin, D. A., Mitchell, C. J., Bowen, R., & Bunning, M. L. (2001) · Journal of Virology · doi:10.1128/jvi.75.9.4040-4047.2001 · Cited by 447
Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, J., Dubois, M.-C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807381 · Cited by 417
Electroporation delivery of DNA vaccines: prospects for success
Sardesai, N. Y., & Weiner, D. B. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.008 · Cited by 416
Vaccines for the twenty-first century society
Rappuoli, R., Mandl, C. W., Black, S., & De Gregorio, E. (2011) · Nature Reviews Immunology · doi:10.1038/nri3085 · Cited by 388
Self-citationGray, G. E., Allen, M., Moodie, Z., Churchyard, G., Bekker, L.-G., Nchabeleng, M., Mlisana, K., Metch, B., de Bruyn, G., Latka, M. H., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70098-6 · Cited by 387
Clinical Applications of DNA Vaccines: Current Progress
Ferraro, B., Morrow, M. P., Hutnick, N. A., Shin, T. H., Lucke, C. E., & Weiner, D. B. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir334 · Cited by 381
Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins
McLellan, J. S., Ray, W. C., & Peeples, M. E. (2013) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-38919-1_4 · Cited by 380
Pulendran, B., Li, S., & Nakaya, H. I. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.006 · Cited by 380
Weide, B., Pascolo, S., Scheel, B., Derhovanessian, E., Pflugfelder, A., Eigentler, T. K., Pawelec, G., Hoerr, I., Rammensee, H.-G., & Garbe, C. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a00068 · Cited by 378 · cited 2×
“To date, several exploratory trials in cancer patients with mRNA vaccines have resulted in the induction of anti-tumor immunity, demonstrating proof of concept in humans (Weide et al , 2008, 2009; Rittig et al , 2011).”
A Blueprint for HIV Vaccine Discovery
Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.09.008 · Cited by 375
Fowler, V. G., Allen, K. B., Moreira, E. D., Moustafa, M., Isgro, F., Boucher, H. W., Corey, G. R., Carmeli, Y., Betts, R., Hartzel, J. S., et al. (2013) · JAMA · doi:10.1001/jama.2013.3010 · Cited by 372
Anderson, P. C. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440150134043 · Cited by 338
Ross, P. J., Sutton, C. E., Higgins, S., Allen, A. C., Walsh, K., Misiak, A., Lavelle, E. C., McLoughlin, R. M., & Mills, K. H. G. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003264 · Cited by 330
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Roper, M. H., Vandelaer, J. H., & Gasse, F. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61261-6 · Cited by 310
Swanson, K. A., Settembre, E. C., Shaw, C. A., Dey, A. K., Rappuoli, R., Mandl, C. W., Dormitzer, P. R., & Carfi, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106536108 · Cited by 285
Self-citationImmunotherapy Against HPV16/18 Generates Potent T H 1 and Cytotoxic Cellular Immune Responses
Bagarazzi, M. L., Yan, J., Morrow, M. P., Shen, X., Parker, R. L., Lee, J. C., Giffear, M., Pankhong, P., Khan, A. S., Broderick, K. E., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004414 · Cited by 282
Flaviviruses and flavivirus vaccines
Heinz, F. X., & Stiasny, K. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.09.114 · Cited by 268
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
Weide, B., Carralot, J.-P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., Rammensee, H.-G., Garbe, C., & Pascolo, S. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815ce501 · Cited by 261 · cited 1×
“To date, several exploratory trials in cancer patients with mRNA vaccines have resulted in the induction of anti-tumor immunity, demonstrating proof of concept in humans (Weide et al , 2008, 2009; Rittig et al , 2011).”
Immunologic Basis of Vaccine Vectors
Liu, M. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.004 · Cited by 237
Jones, C. E. (2011) · JAMA · doi:10.1001/jama.2011.100 · Cited by 236
Kruit, W. H. J., Suciu, S., Dreno, B., Mortier, L., Robert, C., Chiarion-Sileni, V., Maio, M., Testori, A., Dorval, T., Grob, J.-J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7111 · Cited by 227
Rittig, S. M., Haentschel, M., Weimer, K. J., Heine, A., Muller, M. R., Brugger, W., Horger, M. S., Maksimovic, O., Stenzl, A., Hoerr, I., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.289 · Cited by 226
Viral vectors as vaccine platforms: deployment in sight
Rollier, C. S., Reyes-Sandoval, A., Cottingham, M. G., Ewer, K., & Hill, A. V. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.006 · Cited by 203
Guirakhoo, F., Kitchener, S., Morrison, D., Forrat, R., McCarthy, K., Nichols, R., Yoksan, S., Duan, X., Ermak, T. H., Kanesa-Thasan, N., et al. (2006) · Human Vaccines · doi:10.4161/hv.2.2.2555 · Cited by 197
Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics
Dormitzer, P. R., Suphaphiphat, P., Gibson, D. G., Wentworth, D. E., Stockwell, T. B., Algire, M. A., Alperovich, N., Barro, M., Brown, D. M., Craig, S., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006368 · Cited by 196
Self-citationRNA: The new revolution in nucleic acid vaccines
Geall, A. J., Mandl, C. W., & Ulmer, J. B. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.05.001 · Cited by 183
Gray, G., Buchbinder, S., & Duerr, A. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833d2d2b · Cited by 172
10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™
Prymula, R., & Schuerman, L. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.113 · Cited by 172
Olotu, A., Lusingu, J., Leach, A., Lievens, M., Vekemans, J., Msham, S., Lang, T., Gould, J., Dubois, M.-C., Jongert, E., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70262-0 · Cited by 170
Future Vaccination Strategies against Tuberculosis: Thinking outside the Box
Kaufmann, S. H. E. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.015 · Cited by 166
Leroux-Roels, I., Forgus, S., De Boever, F., Clement, F., Demoitié, M.-A., Mettens, P., Moris, P., Ledent, E., Leroux-Roels, G., & Ofori-Anyinam, O. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.05.035 · Cited by 165
Moro, P. L., Broder, K., Zheteyeva, Y., Walton, K., Rohan, P., Sutherland, A., Guh, A., Haber, P., DeStefano, F., & Vellozzi, C. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.08.050 · Cited by 165
Morrison, D., Legg, T. J., Billings, C. W., Forrat, R., Yoksan, S., & Lang, J. (2010) · The Journal of Infectious Diseases · doi:10.1086/649916 · Cited by 165
Garver, K., LaPatra, S., & Kurath, G. (2005) · Diseases of Aquatic Organisms · doi:10.3354/dao064013 · Cited by 164
Flingai, S., Czerwonko, M. E., Goodman, J., Kudchodkar, S. B., Muthumani, K., & Weiner, D. B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00354 · Cited by 160
Vaccine review: “Staphyloccocus aureus vaccines: Problems and prospects”
Jansen, K. U., Girgenti, D., Scully, I. L., & Anderson, A. S. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.04.002 · Cited by 155
Dengue vaccine development: a 75% solution?
Halstead, S. B. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61510-4 · Cited by 141
Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil??)
Siddiqui, M. A. A., & Perry, C. M. (2006) · Drugs · doi:10.2165/00003495-200666090-00008 · Cited by 137
Yellow fever vaccination and pregnancy: a four-year prospective study
Nasidi, A., Monath, T. P. C., Vandenberg, J. I., Tomori, O., Calisher, C. H., Hurtgen, X., Munube, G. R. R., Sorungbe, A. O. O., Okafor, G. C., & Wali, S. M. (1993) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(93)90156-k · Cited by 136
Vaccination and passive immunisation against Staphylococcus aureus
Schaffer, A. C., & Lee, J. C. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.06.009 · Cited by 130
Vaccines for women for preventing neonatal tetanus
Demicheli, V., Barale, A., & Rivetti, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002959.pub4 · Cited by 128
Romanowski, B. (2011) · Human Vaccines · doi:10.4161/hv.7.2.13690 · Cited by 127
Immunology of TLR-independent vaccine adjuvants
Gregorio, E. D., D’Oro, U., & Wack, A. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.003 · Cited by 127
Diagnosis of extrapulmonary tuberculosis using the Xpert®MTB/RIF assay
Lawn, S. D., & Zumla, A. I. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.43 · Cited by 127
Development of a vaccine against Staphylococcus aureus
Spellberg, B. J., & Daum, R. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0293-5 · Cited by 121
La vaccination preventive contre la tuberculose par le "BCG"
Calmette, A. (1927) · Galiciana (Xunta de Galicia) · Cited by 119
Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data
Bejon, P., White, M. T., Olotu, A., Bojang, K., Lusingu, J., Salim, N., Otsyula, N., Agnandji, S. T., Asante, K. P., Owusu‐Agyei, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70005-7 · Cited by 117
Is there a future for a Staphylococcus aureus vaccine?
Proctor, R. A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.11.006 · Cited by 111
Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix???]
Keam, S. J., & Harper, D. M. (2008) · Drugs · doi:10.2165/00003495-200868030-00007 · Cited by 107
Advances in structure-based vaccine design
Kulp, D. W., & Schief, W. R. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.05.010 · Cited by 103
Live-attenuated bacteria as a cancer vaccine vector
Toussaint, B., Chauchet, X., Wang, Y., Polack, B., & Gouëllec, A. L. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.836914 · Cited by 91
Development and registration of recombinant veterinary vaccines
Poulet, H., Minke, J. M. H. M., Pardo, M. C., Juillard, V., Nordgren, B., & Audonnet, J.-C. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.11.066 · Cited by 90
Novel targeted immunotherapy approaches for staphylococcal infection
Otto, M. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.495115 · Cited by 85
Tuberculosis vaccine development: strength lies in tenacity
Kaufmann, S. H. E. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.03.004 · Cited by 74
Vaccines in Pregnant Women and Research Initiatives
Healy, C. M. (2012) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31824f3acb · Cited by 72
Immunotherapeutic strategies to combat staphylococcal infections
Ohlsen, K., & Lorenz, U. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2010.04.015 · Cited by 63
Castillo‐Solórzano, C., Reef, S. E., Morice, A., Vascones, N., Chévez, A. E., Soares, R. C., Torres, C., Vizzotti, C., & Matus, C. R. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir489 · Cited by 58
Harro, C., Betts, R., Orenstein, W., Kwak, E.-J., Greenberg, H. E., Onorato, M. T., Hartzel, J., Lipka, J., DiNubile, M. J., & Kartsonis, N. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00356-10 · Cited by 57 · cited 1×
“More recently, the V710 vaccine, consisting of a single highly conserved S. aureus antigen (IsdB), was shown to be immunogenic in healthy adults and in patients undergoing chronic hemodialysis (Harro et al , 2010, 2012; Moustafa et al , 2012).”
Vaccines for women to prevent neonatal tetanus
Demicheli, V., Barale, A., & Rivetti, A. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002959.pub2 · Cited by 57
Harro, C. D., Betts, R. F., Hartzel, J. S., Onorato, M. T., Lipka, J., Smugar, S. S., & Kartsonis, N. A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.12.045 · Cited by 56
Poxvirus-vectored vaccines for rabies—A review
Weyer, J., Rupprecht, C. E., & Nel, L. H. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.033 · Cited by 53
Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]
Duggan, S. T. (2010) · Drugs · doi:10.2165/11205110-000000000-00000 · Cited by 51
Draghia, R., Li, X., & Schwartz, R. J. (1997) · Nature Biotechnology · doi:10.1038/nbt1197-1285 · Cited by 51
Cost‐Effectiveness of a Potential ProphylacticHelicobacter pyloriVaccine in the United States
Rupnow, M. F. T., Chang, A. H., Shachter, R. D., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/605845 · Cited by 49
Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed)
Sanford, M. (2012) · Drugs · doi:10.2165/11209330-000000000-00000 · Cited by 41
de Cassan, S. C., & Draper, S. J. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.11 · Cited by 34
Koff, W. C., Russell, N. D., Walport, M. J., Feinberg, M. B., Shiver, J. W., Karim, S. S. A., Walker, B. D., McGlynn, M. G., Nweneka, C. V., & Nabel, G. J. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.10.115 · Cited by 33
Cytokine-adjuvanted HIV-DNA vaccination strategies
Lori, F., Weiner, D. B., Calarota, S. A., Kelly, L., & Lisziewicz, J. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0047-y · Cited by 31
Sipuleucel-T in Metastatic Castration-Resistant Prostate Cancer†
Plosker, G. L. (2011) · BioDrugs · doi:10.2165/11207140-000000000-00000 · Cited by 31
Moustafa, M., Aronoff, G. R., Chandran, C. B., Hartzel, J. S., Smugar, S. S., Galphin, C. M., Mailloux, L. U., Brown, E., DiNubile, M. J., Kartsonis, N. A., et al. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00034-12 · Cited by 30
Vaccines for women to prevent neonatal tetanus
Demicheli, V., Barale, A., & Rivetti, A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002959.pub3 · Cited by 29
La Vaccination Préventive Contre la Tuberculose par le “BCG”
Ravenel, M. P. (1928) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.18.8.1075-a · Cited by 27
Plotkin, S. A., & Reef, S. E. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50033-7 · Cited by 23
Simulated Impact of RTS,S/AS01 Vaccination Programs in the Context of Changing Malaria Transmission
Brooks, A., Briët, O., Hardy, D., Steketee, R. W., & Smith, T. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032587 · Cited by 18
Pineau, P., & Tiollais, P. (2009) · Pathologie Biologie · doi:10.1016/j.patbio.2009.03.004 · Cited by 14
Structure-Based Design for High-Hanging Vaccine Fruits
Back, J. W., & Langedijk, J. P. M. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00002-0 · Cited by 9
Cited by
The role of vaccines in combatting antimicrobial resistance
Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 500
Self-citationHuman papillomavirus vaccine against cervical cancer: Opportunity and challenge
Wang, R., Pan, W., Jin, L., Huang, W., Li, Y., Wu, D., Gao, C., Ma, D., & Liao, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.039 · Cited by 493
Understanding modern-day vaccines: what you need to know
Vetter, V., Denizer, G., Friedland, L. R., Krishnan, J., & Shapiro, M. (2018) · Annals of Medicine · doi:10.1080/07853890.2017.1407035 · Cited by 354
Frederiksen, L. S. F., Zhang, Y., Foged, C., & Thakur, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01817 · Cited by 287
Prime-boost vaccine strategy against viral infections: Mechanisms and benefits
Kardani, K., Bolhassani, A., & Shahbazi, S. (2016) · Vaccine · doi:10.1016/j.vaccine.2015.11.062 · Cited by 255
Metadata
- Authors
- Delany, I., Rappuoli, R., & De Gregorio, E.
- Venue
- EMBO Molecular Medicine
- Published
- 2014-05-06
- Volume
- 6
- Issue
- 6
- Pages
- 708-720
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2121049053
- Cited by
- 420
- References
- 116
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.